Dr. Adam Kennah, MD — Medical Director & Clinical Reviewer

Dr. Adam Kennah, MD, is a U.S.-licensed physician who serves as the Medical Director for NexLife—the program selected as GLP Agonists' 2026 Editor's Pick—and as the clinical reviewer-of-record for medication, dosing, contraindication, and pharmacology content across GLP Agonists.

Dr. Kennah's clinical practice focuses on cardiometabolic health, obesity medicine, and the safe prescribing of incretin-based therapies (GLP-1 receptor agonists, dual GIP/GLP-1 agonists, and emerging triple-agonist molecules). He provides oversight on dosing ladders, titration safety, drug-drug interactions, and contraindication screening for clinical content published on this site.

Because Dr. Kennah is the named Medical Director at a provider GLP Agonists reviews favorably, his role is bounded by a hard editorial firewall: he reviews clinical accuracy only, never rankings, never editorial conclusions about NexLife or competitors, and never pricing-comparison content. Disclosure of this dual role is published on every page he reviews and on our conflicts of interest page.

Clinical focus areas

• GLP-1 receptor agonist prescribing (semaglutide, tirzepatide, liraglutide)
• Obesity medicine & metabolic-syndrome management
• Cardiometabolic risk reduction
• Compounded preparation safety standards (USP <797>, <800>)
• Telehealth prescribing protocols & medical-necessity documentation
• Peptide therapy oversight

Editorial role at GLP Agonists

Dr. Kennah reviews every page tagged with a "Fact-checked by Dr. Adam Kennah, MD" line. His review covers: drug-name accuracy, dosing-ladder correctness, contraindication completeness, mechanism-of-action statements, FDA-status references, and interaction-warning currency. He does not review or approve provider rankings, comparison rankings, or editorial language about NexLife's competitive position.